Menu

Evidence into Practice

Tricia Strusowski believes it's important for both novice and seasoned navigators to collaborate in order to learn and help further the profession.
Tricia Strusowski describes some of the goals of the AONN+ Evidence into Practice Committee and expands upon the potential of what the committee can accomplish.
The AONN+ Evidence into Practice Committee would like to extend thanks to all who responded to our recent survey in order to glean members’ knowledge and comfort level in quality, outcomes, performance improvement, and research projects that can be considered research in the broad sense of the word.
New to quality improvement and research and want to know how to begin? The AONN+ Mentorship Workgroup of the Evidence into Practice Committee have made it simple for you.
The role of the navigator along the continuum of care is bidimensional in nature with a patient-centered (empowerment with education and knowledge) and health system (multidisciplinary) orientation to deliver timely, seamless care. Within the multidisciplinary team, the navigator works as an advocate, care provider, educator, counselor, and facilitator to ensure that every patient receives comprehensive, timely, and quality healthcare services.
As co-chair of the Evidence into Practice Committee, Danelle Johnston explains the committee's goals and how they aim to improve quality outcomes.
Vanessa Rodriguez discusses the Evidence into Practice Committee and how it is working to help provide a roadmap to navigators.
The scope of navigation has evolved from the Freeman model of community outreach and prevention to spanning the entire continuum of care for oncology patients. Navigators help individuals overcome barriers to care and navigate through the screening/diagnostic, treatment, survivorship, and end-of-life care continuum.
The case study for this discussion highlights the complexities of care coordination when patients arrive unprepared physically or mentally for the recommended medical treatments as determined by guidelines. It also shows how navigators can assemble needed care team players to efficiently guide the patient through prehabilitation and preparation for medical treatment.
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.
Page 1 of 2
Results 1 - 10 of 13

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Thank you to our Corporate Sponsors and Alliance Partners!

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • National Alliance Partner

    National Alliance Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner